Viking Therapeutics Inc (NASDAQ: VKTX) on Tuesday, plunged -5.15% from the previous trading day, before settling in for the closing price of $27.96. Within the past 52 weeks, VKTX’s price has moved between $24.41 and $89.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -57.98%. With a float of $108.93 million, this company’s outstanding shares have now reached $111.57 million.
Let’s determine the extent of company efficiency that accounts for 36 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Viking Therapeutics Inc (VKTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Viking Therapeutics Inc is 2.96%, while institutional ownership is 73.71%. The most recent insider transaction that took place on Jan 06 ’25, was worth 8,313,601. In this transaction President & CEO of this company sold 194,490 shares at a rate of $42.75, taking the stock ownership to the 2,366,570 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Chief Operating Officer sold 54,215 for $42.75, making the entire transaction worth $2,317,599. This insider now owns 374,134 shares in total.
Viking Therapeutics Inc (VKTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -57.98% per share during the next fiscal year.
Viking Therapeutics Inc (NASDAQ: VKTX) Trading Performance Indicators
Viking Therapeutics Inc (VKTX) is currently performing well based on its current performance indicators. A quick ratio of 33.09 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.01, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -2.16 in one year’s time.
Technical Analysis of Viking Therapeutics Inc (VKTX)
Looking closely at Viking Therapeutics Inc (NASDAQ: VKTX), its last 5-days average volume was 4.15 million, which is a drop from its year-to-date volume of 4.59 million. As of the previous 9 days, the stock’s Stochastic %D was 56.16%. Additionally, its Average True Range was 2.56.
During the past 100 days, Viking Therapeutics Inc’s (VKTX) raw stochastic average was set at 3.69%, which indicates a significant decrease from 17.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.94% in the past 14 days, which was higher than the 82.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $33.28, while its 200-day Moving Average is $51.78. However, in the short run, Viking Therapeutics Inc’s stock first resistance to watch stands at $27.41. Second resistance stands at $28.29. The third major resistance level sits at $29.78. If the price goes on to break the first support level at $25.04, it is likely to go to the next support level at $23.55. Now, if the price goes above the second support level, the third support stands at $22.67.
Viking Therapeutics Inc (NASDAQ: VKTX) Key Stats
Market capitalization of the company is 2.98 billion based on 112,248K outstanding shares. Right now, sales total 0 K and income totals -109,960 K. The company made 0 K in profit during its latest quarter, and -35,420 K in sales during its previous quarter.
